# Mixed Movement Disorder Caused by ADCY5 Pathogenic Variant Successfully Treated With Caffeine: A Case From Ukraine

## TL;DR

A rare movement disorder caused by an ADCY5 gene variant was successfully treated with high-dose caffeine in a Ukrainian patient.

## Contribution

First reported case of a Ukrainian patient with MxMD-ADCY5 showing dramatic improvement with caffeine.

## Key findings

- High-dose caffeine (600 mg/day) significantly improved paroxysmal dyskinesia in an adult patient with MxMD-ADCY5.
- No adverse events were observed during a 6-month follow-up period.
- Caffeine may be an effective treatment option for managing dyskinesia in MxMD-ADCY5.

## Abstract

Mixed movement disorder due to pathogenic variants in the ADCY5 gene (MxMD‐ADCY5) is a rare condition characterized predominantly by paroxysmal involuntary choreiform movements involving the limbs, face, and neck, often accompanied by dystonia and myoclonus. Speech disturbances, delayed motor development, cognitive impairment, axial hypotonia, and episodic exacerbations of dyskinesia are also common features. Currently, treatment strategies remain limited; however, several studies indicate a beneficial effect of caffeine in the management of dyskinesia.

This clinical report aims to present a case of MxMD‐ADCY5 showing a high therapeutic response to caffeine. To our knowledge, this is the first reported Ukrainian patient with this condition demonstrating dramatic improvement in paroxysmal dyskinesia after treatment with high‐dose caffeine.

In our clinical observation, administration of caffeine at a total daily dose of 600 mg resulted in significant clinical improvement in an adult patient with MxMD-ADCY5 over a follow‐up period of at least 6 months. No adverse events or side effects were reported.